文献速递炎症性肠病

体重指数未影响依曲莫德疗效与安全性:ELEVATE溃疡性结肠炎临床项目的事后分析

Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program.
PubMed 文献 · Am J Gastroenterol · 2025-01-29

该事后分析基于ELEVATE UC 52和ELEVATE UC 12,按体重指数(BMI)分层评估依曲莫德2 mg每日一次治疗中重度活动性溃疡性结肠炎的疗效与安全性。结果显示各BMI亚组中依曲莫德较安慰剂在临床缓解等多终点上均更优,安全性一致,高BMI未显著影响疗效与安全性。

要点

  • BMI<25 kg/m²者第12周临床缓解率依曲莫德27.9% vs 安慰剂13.3%(P<0.001)。
  • BMI 25-30 kg/m²者第52周临床缓解率依曲莫德33.3% vs 安慰剂6.3%(P<0.0001)。
  • BMI>30 kg/m²者第52周临床缓解率依曲莫德36.5% vs 安慰剂3.9%(P<0.0001)。

核心结论

  • 高BMI未显著影响依曲莫德的疗效与安全性结局。

研究设计与样本

  • ELEVATE UC 52和ELEVATE UC 12的事后分析,患者接受依曲莫德2 mg每日一次或安慰剂,按BMI<25、25-30、>30 kg/m²分层。

主要发现

  • BMI<25 kg/m²组(N=443)第12周临床缓解率依曲莫德27.9% vs 安慰剂13.3%,第52周30.8% vs 10.0%(均P<0.0001)。
  • BMI 25-30 kg/m²组(N=217)第12周临床缓解率依曲莫德28.5% vs 安慰剂10.0%(P<0.001),第52周33.3% vs 6.3%(P<0.0001)。
  • BMI>30 kg/m²组(N=127)第52周临床缓解率依曲莫德36.5% vs 安慰剂3.9%(P<0.0001)。
  • 无论基线BMI,治疗应答者中依曲莫德组粪便钙卫蛋白水平数值上低于安慰剂组。
  • 依曲莫德的安全性特征在各BMI亚组间一致。

关键数值与推荐

  • BMI<25 kg/m²和25-30 kg/m²亚组中,依曲莫德较安慰剂在第12周和第52周临床缓解及所有其他疗效终点均更优(P<0.05)。
  • BMI>30 kg/m²亚组中,依曲莫德较安慰剂在第52周临床缓解及第12周和第52周大多数其他疗效终点均更优(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: High body mass index (BMI) may reduce ulcerative colitis (UC) treatment efficacy. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate 1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post hoc analysis assessed treatment outcomes according to BMI in ELEVATE UC 52 and ELEVATE UC 12. METHODS: Patients receiving etrasimod 2 mg QD or placebo were stratified by BMI: <25, 25-30, and >30 kg/m 2 . Efficacy and safety were assessed at weeks 12 (pooled data) and 52 (ELEVATE UC 52 only) in addition to biomarkers assessments from week 0-12. RESULTS: For BMI <25 (N = 443) and 25-30 kg/m 2 (N = 217) subgroups, more patients receiving etrasimod vs placebo achieved clinical remission at weeks 12 (BMI <25 kg/m 2 : 27.9% vs 13.3%; 25-30 kg/m 2 : 28.5% vs 10.0%; all P < 0.001) and 52 (BMI <25 kg/m 2 : 30.8% vs 10.0%; 25-30 kg/m 2 : 33.3% vs 6.3%; all P < 0.0001), and also for all other efficacy end points ( P < 0.05). In the BMI >30 kg/m 2 subgroup (N = 127), more patients receiving etrasimod vs placebo achieved clinical remission at week 52 (36.5% vs 3.9%; P < 0.0001) and most other efficacy end points at weeks 12 and 52 (all P < 0.05). Overall, regardless of baseline BMI, numerically lower fecal calprotectin levels were observed with etrasimod vs placebo in treatment responders. The safety profile of etrasimod was consistent between BMI subgroups. DISCUSSION: A high BMI did not significantly affect efficacy and safety outcomes of etrasimod (NCT03945188; NCT03996369).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yarur AJ, Long MD, Torres J, et al. Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program. Am J Gastroenterol. 2025. PMID: 39878434. doi:10.14309/ajg.0000000000003330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。